GENZYME POLYCLONALS SAS : revenue, balance sheet and financial ratios

GENZYME POLYCLONALS SAS is a French company founded 28 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in LYON (69007), this company of category GE shows in 2024 a revenue of 347.2 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - GENZYME POLYCLONALS SAS (SIREN 418661039)
Indicator 2024 2023 2022 2021 2020 2019 2017
Revenue 347 248 000 € 237 722 000 € 231 814 000 € 199 169 000 € 99 203 000 € 108 747 000 € 92 360 €
Net income 96 292 000 € 105 862 000 € 92 552 000 € 78 338 000 € 56 376 000 € 69 758 000 € 57 916 €
EBITDA 572 048 000 € 349 032 000 € 134 817 000 € 106 801 000 € 13 160 000 € 33 990 000 € 161 403 €
Net margin 27.7% 44.5% 39.9% 39.3% 56.8% 64.1% 62.7%

Revenue and income statement

In 2024, GENZYME POLYCLONALS SAS achieves revenue of 347.2 M€. Over the period 2017-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +224.1%. Vs 2023, growth of +46% (237.7 M€ -> 347.2 M€). After deducting consumption (-222.0 M€), gross margin stands at 569.2 M€, i.e. a rate of 164%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 572.0 M€, representing 164.7% of revenue. Positive scissor effect: EBITDA margin improves by +17.9 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 96.3 M€, i.e. 27.7% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

347 248 000 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

569 199 000 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

572 048 000 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

122 636 000 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

96 292 000 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

164.7%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 85%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Cash flow represents 47.3% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.0%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

85.278%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

47.302%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.0

Solvency indicators evolution
GENZYME POLYCLONALS SAS

Sector positioning

Debt ratio
0.0 2024
2022
2023
2024
Q1: 0.0
Med: 5.92
Q3: 43.75
Excellent

In 2024, the debt ratio of GENZYME POLYCLONALS SAS (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
85.28% 2024
2022
2023
2024
Q1: 28.05%
Med: 51.52%
Q3: 72.2%
Excellent

In 2024, the financial autonomy of GENZYME POLYCLONALS SAS (85.3%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Repayment capacity
0.0 years 2024
2022
2023
2024
Q1: 0.0 years
Med: 0.01 years
Q3: 1.74 years
Excellent

In 2024, the repayment capacity of GENZYME POLYCLONALS SAS (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. WCR is negative (-1 days): operations structurally generate cash. Notable WCR improvement over the period (-170707%), freeing up cash.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

-604 212 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

-118 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

-1 j

WCR and payment terms evolution
GENZYME POLYCLONALS SAS

Positioning of GENZYME POLYCLONALS SAS in its sector

Comparison with sector Fabrication de préparations pharmaceutiques

Valuation estimate

Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions). This range of 19 212 108€ to 59 050 512€ is provided for information purposes only and requires in-depth analysis to be confirmed.

Estimated enterprise value 2024
Indicative
19212k€ 43375k€ 59050k€
43 375 358 € Range: 19 212 108€ - 59 050 512€
NAF 5 all-time
How is this estimate calculated?

This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fabrication de préparations pharmaceutiques)

Compare GENZYME POLYCLONALS SAS with other companies in the same sector:

Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques

Frequently asked questions about GENZYME POLYCLONALS SAS

What is the revenue of GENZYME POLYCLONALS SAS ?

The revenue of GENZYME POLYCLONALS SAS in 2024 is 347.2 M€.

Is GENZYME POLYCLONALS SAS profitable?

Yes, GENZYME POLYCLONALS SAS generated a net profit of 96.3 M€ in 2024.

Where is the headquarters of GENZYME POLYCLONALS SAS ?

The headquarters of GENZYME POLYCLONALS SAS is located in LYON (69007), in the department Rhone.

Where to find the tax return of GENZYME POLYCLONALS SAS ?

The tax return of GENZYME POLYCLONALS SAS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does GENZYME POLYCLONALS SAS operate?

GENZYME POLYCLONALS SAS operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.